Department of Medical Physiopathology, Sapienza University of Rome, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2012 May;16(5):575-81.
PCOS is the main cause of infertility due to metabolic, hormonal and ovarian dysfunctions. Women affected by PCOS often suffer of insulin resistance and of a compensatory hyperinsulinemia. These conditions put the patients at risk of developing several metabolic disorders. Both myo-inositol (MI) and D-chiro inositol (DCI) glycans administration has been reported to exert beneficial effects at metabolic, hormonal and ovarian level. Beside these common features, MI and DCI are indeed different molecules: they belong to two different signal cascades and regulate different biological processes.
In this study, we aim to verify whether the two molecules have a synergistic action by acting on their specific cellular pathways. The effectiveness in reducing the risk of metabolic syndrome as well as in enhancing the ovarian functions of a combined therapy with MI and DCI was compared to a mono therapy in a randomized controlled trial.
Fifty overweight women with PCOS were enrolled and divided in two groups to receive MI and DCL (MI+DCI group) or MI alone (MI group) for a period of six months. Baseline measurements were repeated at three months (T1) and at the end of the treatment (T2).
At the end of the treatment, both MI and MI+DCI groups showed an improvement of the metabolic parameters and no significant differences were found. As expected, the combined supplementation with MI and DCI resulted to be more effective, compared to the MI group, after three months of treatment.
The combined administration of MI and DCI in physiological plasma ratio (40:1) should be considered as the first line approach in PCOS overweight patients, being able to reduce the metabolic and clinical alteration of PCOS and, therefore, reduce the risk of metabolic syndrome.
多囊卵巢综合征（PCOS）是导致不孕的主要原因，其与代谢、激素和卵巢功能障碍有关。患有 PCOS 的女性通常会出现胰岛素抵抗和代偿性高胰岛素血症。这些情况使患者有发生多种代谢紊乱的风险。已有研究报道肌醇（MI）和 D-手性肌醇（DCI）聚糖的给药在代谢、激素和卵巢水平均具有有益作用。除了这些共同特征外，MI 和 DCI 实际上是两种不同的分子：它们属于两个不同的信号级联，调节不同的生物学过程。
在这项研究中，我们旨在通过作用于其特定的细胞途径来验证这两种分子是否具有协同作用。通过随机对照试验比较 MI 和 DCI 联合治疗与单一治疗在降低代谢综合征风险以及增强卵巢功能方面的效果。
共纳入 50 名超重的 PCOS 女性患者，并将其分为两组，分别接受 MI 和 DCL（MI+DCI 组）或 MI 单独治疗（MI 组），治疗时间为 6 个月。在 3 个月（T1）和治疗结束时（T2）重复基线测量。
治疗结束时，MI 和 MI+DCI 两组的代谢参数均有所改善，但组间无显著差异。正如预期的那样，与 MI 组相比，联合补充 MI 和 DCI 在治疗 3 个月后效果更为显著。
在生理血浆比例（40:1）下联合使用 MI 和 DCI 应作为超重 PCOS 患者的一线治疗方法，能够减轻 PCOS 的代谢和临床改变，从而降低代谢综合征的风险。
